Progensa™ PCA3 test for prostate cancer (Q39771683)

14 September 2017

title

Progensa™ PCA3 test for prostate cancer (English)

1 reference

14 September 2017

1 reference

Xavier Durand

1

1 reference

14 September 2017

Stephane Moutereau

series ordinal

2

1 reference

14 September 2017

Evanguelos Xylinas

series ordinal

3

1 reference

14 September 2017

Alexandre de la Taille

series ordinal

4

1 reference

14 September 2017

publication date

1 March 2011

1 reference

Expert Review of Molecular Diagnostics: new diagnostic technologies are set to revolutionise healthcare

14 September 2017

published in

1 reference

14 September 2017

volume

11

1 reference

14 September 2017

issue

2

1 reference

14 September 2017

page(s)

137-144

1 reference

14 September 2017

cites work

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.122

Estimates of the cancer incidence and mortality in Europe in 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.122

Secular trends in prostate cancer mortality, incidence and treatment: England and Wales, 1975-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.122

DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.122

Molecular PCA3 diagnostics on prostatic fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.122

Performance of the gen-probe transcription-mediated [corrected] amplification research assay compared to that of a multitarget real-time PCR for Mycoplasma genitalium detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.122

Comparison of transcription-mediated amplification and PCR assay results for various genital specimen types for detection of Mycoplasma genitalium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.122

A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.122

APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.122

DD3PCA3 RNA analysis in urine--a new perspective for detecting prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.122

uPM3, a new molecular urine test for the detection of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.122

The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.122

PCA3: a molecular urine assay for predicting prostate biopsy outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.122

Rational approach to implementation of prostate cancer antigen 3 into clinical care

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.122

Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.122

Risk of prostate cancer on first re-biopsy within 1 year following a diagnosis of high grade prostatic intraepithelial neoplasia is related to the number of cores sampled

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.122

Urinary prostate cancer 3 test: toward the age of reason?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.122

PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.122

Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.122

The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.122

Follow-up of men with an elevated PCA3 score and a negative biopsy: does an elevated PCA3 score indeed predict the presence of prostate cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.122

Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.122

PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.122

PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.122

Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.122

Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.122

Re: Accuracy of PCA3 Measurement in Predicting Short-Term Biopsy Progression in an Active Surveillance Program J. J. Tosoian, S. Loeb, A. Kettermann, P. Landis, D. J. Elliot, J. I. Epstein, A. W. Partin, H. B. Carter and L. J. Sokoll J Urol 2010; 18

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.122

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.122

Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.122

A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.122

Combined analysis of multiple mRNA markers by RT-PCR assay for prostate cancer diagnosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.122

A duplex quantitative polymerase chain reaction assay based on quantification of alpha-methylacyl-CoA racemase transcripts and prostate cancer antigen 3 in urine sediments improved diagnostic accuracy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.122

21 January 2018

Identifiers

DOI

10.1586/ERM.10.122

1 reference

14 September 2017

1 reference